Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026 in Padua, Italy. Founded in 1963, AEPC is the world’s largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries and beyond. Its members are united by a commitment to advancing the practice of congenital and paediatric cardiology and improving outcomes for patients with heart disease.
This year’s meeting is hosted by the University of Padova – one of the world’s oldest and most prestigious institutions – and features a scientific program centred on advanced cardiovascular imaging and artificial intelligence. These are areas where Ventripoint is driving meaningful clinical progress. Ventripoint will exhibit alongside its European distributor, AngioPro, welcoming existing customers and engaging with clinicians from the global congenital cardiology community. A key focus at the booth will be the power of supporting evolution of cardiac function over time of congenital heart disease (CHD) patients using VMS+™.
The importance of this approach is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease – co-endorsed by AEPC – which identify CHD as a lifelong chronic condition requiring structured, individualised follow-up, and affirm echocardiography as the key modality for longitudinal assessment of ventricular function (Baumgartner et al., European Heart Journal, 2021; doi:10.1093/eurheartj/ehaa554).
Ventripoint’s priority for 2026 is accelerating the integration of VMS+™ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients. The latest release, VMS+™ 4.0, was purpose-built around the needs of clinicians – streamlining workflows, reducing the time required to generate assessments, and making advanced cardiac analysis accessible at the point of care. At the point of a patient’s first echocardiogram, VMS+™ provides accurate volumetric cardiac measurements equivalent to MRI – detailed insights that arrive early in the care journey, supporting clinical decision-making and more effective patient management across a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
The implications of this announcement are significant for the congenital cardiology field. By demonstrating VMS+™ at AEPC, Ventripoint is positioning its technology as a key enabler of the ESC guidelines’ recommendation for lifelong, individualized follow-up of CHD patients. For clinicians, the ability to obtain MRI-equivalent volumetric measurements from a routine echocardiogram could transform how they monitor disease progression and make treatment decisions. For patients, it means more timely and precise assessments without the cost and complexity of MRI. For the healthcare system, wider adoption of VMS+™ could lead to more efficient care pathways and reduced long-term costs by catching complications earlier. The company’s focus on integrating AI into point-of-care echocardiography aligns with broader trends in digital health and precision medicine, potentially setting a new standard for cardiac imaging in congenital heart disease.
